NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX): Losses Worsen While 54.9% Projected Revenue Growth Tests Bullish Narratives
ImmunityBio (IBRX) reported another unprofitable period, with losses accelerating at a 15% annual rate over the past five years and net profit margins failing to show improvement. Forecasts suggest the company will remain unprofitable for at least the next three years. However, revenue is projected to surge by 54.9% per year, far outpacing the broader US market's 10.4% average growth rate. Investors now face the challenge of weighing a robust revenue outlook against ongoing losses and high...